On July 23, Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-OR) released the Chairman’s Mark of the Prescription Drug Pricing Reduction Act (PDPRA) of 2019, bipartisan legislation to reduce health care costs. AMCP will continue to engage with staff on the Finance committee on these provisions as we have with Members and staff on the Senate Health, Education, Labor, and Pensions (HELP) Committee.
AMCP CEO Blog: We live in an interconnected world where the marketplace for all things is global. But we must also make sure the global system works for the benefit of the patients we serve. That includes taking steps to ensure the long-term stability and integrity of our critical pharmaceutical supply chain.
Press Release: The Trump Administration today pulled its proposed rule to eliminate safe harbor protections for rebates paid by pharmaceutical manufacturers to PBMs and health plans in Medicare and Medicaid programs.
Press Release: Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”
The Academy of Managed Care Pharmacy (AMCP) is pleased to share our thoughts on the “Lower Health Care Costs Act” (“the Act”) as released on May 23, 2019 by the Committee on Health, Education, Labor and Pensions (“HELP Committee”).
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of the National Coordinator for Health Information Technology (ONC) for the opportunity to provide comments in response to its proposed rule “21st Century Cures Act: Interoperability, Information Blocking, and the Health IT Certification Program” published in the Federal Register on March 4, 2019. AMCP appreciates ONC’s effort to remove barriers to interoperability and health information exchange.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to comment on its public hearing on Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products [FDA-2019-N-1132].
As stakeholders that support patient access to affordable medicines and competition in the pharmaceutical marketplace, we applaud the Food and Drug Administration’s (FDA) efforts to foster the development of biosimilar medicines for America’s patients.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the updated draft industry guidance on “Nonproprietary Naming of Biological Products” published in the Federal Register on March 8, 2019. AMCP appreciates FDA’s ongoing efforts to issue and update guidance that allow health care providers to safely and effectively use biosimilar products.